CG Oncology, Inc. Common stock
CGONNASDAQHealthcare● Active
$53.72
$-2.37(-4.23%)
Market Cap$4.7B
P/E Ratio—
52W High$75.5
52W Low$23.65
CG Oncology, Inc. Common stock (CGON) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CGON · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 8, 2026EPS Actual
-$0.71
Est. -$0.58 · -22.4%
Revenue
$0.00B
Est. $0.00B · +139.1%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 8, 2026
After Market Close
▼ Miss EPS▲ Beat Revenue
CGON reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.07
Rev. $15.39B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.07
Rev. Est.$15.39B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 7, 2026 | -$0.70 | — | — | — | $0.00B | — |
| ▼ Q2 FY2026 | May 8, 2026 | -$0.58 | -$0.71 | -22.4% | $0.00B | $0.00B | +139.1% |
| ▲ Q1 FY2026 | Feb 27, 2026 | -$0.61 | -$0.51 | +16.4% | $0.00B | $0.00B | +412.9% |
| ▼ Q4 FY2025 | Nov 14, 2025 | -$0.56 | -$0.57 | -2.0% | $0.00B | $0.00B | +2706.4% |
| ▼ Q3 FY2025 | Aug 8, 2025 | -$0.49 | -$0.54 | -10.2% | — | $0.00B | — |
| ▼ Q2 FY2025 | May 13, 2025 | -$0.39 | -$0.45 | -15.4% | $0.00B | $0.00B | -56.0% |
| ▼ Q1 FY2025 | Mar 28, 2025 | -$0.41 | -$0.48 | -17.1% | $0.00B | $0.00B | +267.9% |
| ◌ Q4 FY2024 | Nov 14, 2024 | -$0.42 | — | — | — | — | — |
Q3 FY2026
Aug 7, 2026
EPS Actual
—
EPS Est.
-$0.70
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 8, 2026Miss
EPS Actual
-$0.71
EPS Est.
-$0.58
EPS Surpr.
-22.4%
Revenue
$0.00B
Q1 FY2026
Feb 27, 2026Beat
EPS Actual
-$0.51
EPS Est.
-$0.61
EPS Surpr.
+16.4%
Revenue
$0.00B
Q4 FY2025
Nov 14, 2025Miss
EPS Actual
-$0.57
EPS Est.
-$0.56
EPS Surpr.
-2.0%
Revenue
$0.00B
Q3 FY2025
Aug 8, 2025Miss
EPS Actual
-$0.54
EPS Est.
-$0.49
EPS Surpr.
-10.2%
Revenue
—
Q2 FY2025
May 13, 2025Miss
EPS Actual
-$0.45
EPS Est.
-$0.39
EPS Surpr.
-15.4%
Revenue
$0.00B
Q1 FY2025
Mar 28, 2025Miss
EPS Actual
-$0.48
EPS Est.
-$0.41
EPS Surpr.
-17.1%
Revenue
$0.00B
Q4 FY2024
Nov 14, 2024
EPS Actual
—
EPS Est.
-$0.42
EPS Surpr.
—
Revenue
—
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-1.97 | $-0.60 | $0.10 | 3 |
| Q3 FY2027 | $-2.44 | $-0.75 | $0.12 | 4 |
| Q2 FY2027 | $-2.65 | $-0.81 | $0.13 | 3 |
| Q1 FY2027 | $-2.90 | $-0.89 | $0.15 | 3 |
| Q4 FY2026 | $-2.16 | $-0.66 | $0.11 | 7 |
| Q3 FY2026 | $-0.77 | $-0.70 | $-0.63 | 9 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.1B | 7 |
| Q3 FY2027 | $0.0B | $0.0B | $0.1B | 4 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 6 |
| Q1 FY2027 | $0.0B | $0.0B | $0.1B | 4 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 7 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 8 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 8, 2026 | -22.4% | $69.18 | $69.62 | +0.64% |
| ▲ Q1 FY2026 | Feb 27, 2026 | +16.4% | $56.11 | $58.80 | +4.79% |
| ▼ Q4 FY2025 | Nov 14, 2025 | -2.0% | $37.76 | $41.01 | +8.61% |
| ▼ Q3 FY2025 | Aug 8, 2025 | -10.2% | $24.35 | $24.85 | +2.05% |
| ▼ Q2 FY2025 | May 13, 2025 | -15.4% | $25.16 | $24.18 | -3.90% |
| ▼ Q1 FY2025 | Mar 28, 2025 | -17.1% | $26.94 | $26.42 | -1.93% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +33.3% | $31.06 | $33.24 | +7.02% |
| ▼ Q2 FY2024 | May 9, 2024 | -2.9% | $32.43 | $30.02 | -7.43% |
Q2 FY2026+0.64%
Report Date
May 8, 2026
EPS Beat/Miss
-22.4%
Price Before
$69.18
Price After
$69.62
Q1 FY2026+4.79%
Report Date
Feb 27, 2026
EPS Beat/Miss
+16.4%
Price Before
$56.11
Price After
$58.80
Q4 FY2025+8.61%
Report Date
Nov 14, 2025
EPS Beat/Miss
-2.0%
Price Before
$37.76
Price After
$41.01
Q3 FY2025+2.05%
Report Date
Aug 8, 2025
EPS Beat/Miss
-10.2%
Price Before
$24.35
Price After
$24.85
Q2 FY2025-3.90%
Report Date
May 13, 2025
EPS Beat/Miss
-15.4%
Price Before
$25.16
Price After
$24.18
Q1 FY2025-1.93%
Report Date
Mar 28, 2025
EPS Beat/Miss
-17.1%
Price Before
$26.94
Price After
$26.42
Q3 FY2024+7.02%
Report Date
Aug 8, 2024
EPS Beat/Miss
+33.3%
Price Before
$31.06
Price After
$33.24
Q2 FY2024-7.43%
Report Date
May 9, 2024
EPS Beat/Miss
-2.9%
Price Before
$32.43
Price After
$30.02
Avg Beat Reaction+5.90%
Avg Miss Reaction-0.33%
Beat Rate2 / 8 quarters
Largest Move+8.61% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CGON ends December
CG Oncology, Inc. Common stock (CGON) most recently reported earnings on May 8, 2026 for Q2 FY2026, posting EPS of $-0.71 — missing the analyst consensus of $-0.58 by -22.4%. The next CGON earnings date is expected around September 1, 2026.
Each quarter, investors track CGON earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CGON revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CGON's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CGON earnings · 5 questionsCG Oncology, Inc. Common stock's next earnings report is expected around September 1, 2026. CGON typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CGON historically reports after market close (AMC).
CGON earnings datewhen is CGON earningsCGON next earnings datewhen does CGON report earningsCGON earnings calendar
▸ Source: FMP · CG Oncology, Inc. Common stock SEC filings · US GAAP · CG Oncology, Inc. Common stock SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026